ID: ALA2022927

Max Phase: Preclinical

Molecular Formula: C22H22N2O5

Molecular Weight: 304.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  C#CCN(C)Cc1cc2cc(OCc3ccccc3)ccc2[nH]1.O=C(O)C(=O)O

Standard InChI:  InChI=1S/C20H20N2O.C2H2O4/c1-3-11-22(2)14-18-12-17-13-19(9-10-20(17)21-18)23-15-16-7-5-4-6-8-16;3-1(4)2(5)6/h1,4-10,12-13,21H,11,14-15H2,2H3;(H,3,4)(H,5,6)

Standard InChI Key:  RDFDFPKQCZKUQW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 304.39

Molecular Weight (Monoisotopic): 304.1576

AlogP: 3.81

#Rotatable Bonds: 6

Polar Surface Area: 28.26

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.61

CX LogP: 3.73

CX LogD: 3.31

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.70

Np Likeness Score: -1.11

References

1. Samadi A, de los Ríos C, Bolea I, Chioua M, Iriepa I, Moraleda I, Bartolini M, Andrisano V, Gálvez E, Valderas C, Unzeta M, Marco-Contelles J..  (2012)  Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.,  52  [PMID:22503231] [10.1016/j.ejmech.2012.03.022]

2. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of IQOG CSIS (Spain) compounds,  [10.6019/CHEMBL4513135]

Source

Source(2):

• Scientific Literature
• CO-ADD antimicrobial screening data